u/niels_norgaard

Which receptor family are you attributing that effect to?

Careful, that pricing figure is a headline offer with conditions attached rather than the actual monthly cost.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

formulary decisions are provincial, so the province is the first fact

Powder or already in solution?

Plan and policy numbers redacted from the screenshot above.

Agreed — write the application against the published criteria rather than around them.

Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

small molecule, not a peptide, and that changes everything about it

Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.

I would not read one pharmacy’s cash price as the going rate. The spread is real.

Asked QST which lines they hold regionally and got a straight list back. That answered my summer ordering question completely.

Correcting myself: it was a quantity limit rather than a denial, which changes the whole process.

Criteria changed at plan renewal and the denial that had been immovable simply did not apply any more.

Agreed on keeping letters. Dates are what make an appeal or a re-referral possible.

Those criteria were revised at renewal, so the version quoted upthread is out of date.

solene_eriksen is right that a rejected claim and a denied authorization are different animals.

Was this a denied authorization or a rejected claim?

Which trial, and which arm?

That is the first-month offer price, not the ongoing monthly cost. The tracker records the second one.

private and NHS pathways are not a ladder, they are separate routes

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.